Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis

Autor: David L. Wyles, Yves Horsmans, Erica Villa, Sarah Kopecky-Bromberg, Tania M. Welzel, Armen Asatryan, Preethi Krishnan, Federico J. Mensa, Stephen D. Ryder, Roger Trinh, Ola Weiland, David Mutimer, Peter Ruane, Stanley Wang, Edward Gane, Teresa I. Ng, Jürgen K. Rockstroh, Sandra S. Lovell, Zhenyi Xue, Jeong Heo, Kosh Agarwal, Paul Y. Kwo, Steven L. Flamm

Publikováno v: Journal of Viral Hepatitis
Journal of viral hepatitis, Vol. 26, no. 3, p. 337-349 (2019)

Summary Glecaprevir coformulated with pibrentasvir (G/P) is approved to treat hepatitis C virus (HCV) infection and was highly efficacious in phase 2 and 3 studies. Treating HCV genotype (GT) 3 infection remains a priority, as these patients are hard

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5cd9e034b34fe732ed08057948ded30
https://doi.org/10.1111/jvh.13038

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure

Autor: David R. Shaw, Yang Lei, Joel Gallant, Robert Reindollar, Sarah Kopecky-Bromberg, Stephen Pianko, Maria Buti, Stanislas Pol, Jens Kort, Armen Asatryan, Michael W. Fried, Preethi Krishnan, C.-W. Lin, Stuart C. Gordon, Fred Poordad, Christophe Hézode, Federico J. Mensa, Franco Felizarta, Teresa I. Ng, David E. Bernstein

Publikováno v: Hepatology (Baltimore, Md.)

Methods: MAGELLAN-1 Part 2 was a randomized, open-label, phase 3 study to evaluate the efficacy and safety of ribavirin (RBV)-free glecaprevir and pibrentasvir (G/P; 300 mg/120 mg) in patients with chronic HCV and prior virologic failure on at least

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::134f71533e69d468f368f6e948adc780
https://doi.org/10.1002/hep.29671

[Efficacy and safety of paritaprevir/ritonavir/ombitasvir combined with dasabuvir in non-cirrhotic Asian adult patients with newly diagnosed and treated chronic HCV genotype 1b infection: a randomized, double-blind, placebo-controlled study - China data].

Autor: Wei L; Peking University People's Hospital, Beijing 100044, China., Cheng J; Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China., Luo J; AbbVie Inc., North Chicago 60064, IL, USA., Li ZP; Jiangsu Province Hospital, Nanjing 210029, China., Duan JL; Beijing You'an Hospital, Capital Medical University, Beijing 100069, China., Hou JD; Nan Fang Hospital, Guangzhou 510515, China., Jia MX; Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China., Zhang Y; Shenyang 6th People's Hospital, Shenyang 110006, China., Huang Q; Xiangya Hospital Central South University, Changsha 410008, China., Xie GJ; Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China., Wang DL; Peking University First Hospital, Beijing 100034, China., Yang W; Union Hospital Tongji Mecical College, Huazhong University of Science and Technology, Wuhan 430022, China., Zhao CY; Nanjing 2nd Hospital, Nanjing 210028, China., Zhao G; The 3rd Hospital of Hebei Medical University, Shijiazhuang 500000, China., Tang SM; West China School of Medicine, Chengdu 610041, China., Lin GZ; The 1st Hospital of Xi'an Jiaotong Univeersity, Xi'an 710065, China., Gong JJ; The 2nd Hospital of Central South University, Changsha 410011, China., Niu ZL; The 1st Hospital of Jilin University, Changchun 130021, China., Gao JF; The 3rd Hospital, Sun Yay-sen Hospital, Guangzhou 510630, China., Sarah KB; AbbVie Inc., North Chicago 60064, IL, USA., Linda F; AbbVie Inc., North Chicago 60064, IL, USA., Niloufar M; AbbVie Inc., North Chicago 60064, IL, USA., Wang Y; AbbVie. China. Shanghai 200041, China., Wang J; Shanghai Public Health Clinical Center, Shanghai 201508, China.

Publikováno v: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology [Zhonghua Gan Zang Bing Za Zhi] 2018 May 20; Vol. 26 (5), pp. 359-364.